Form 4: PACB CFO Gibson Receives Significant Equity Grant

Pacific Biosciences of California's CFO, James R. Gibson II, was granted 333,848 Restricted Stock Units and options to purchase 667,696 shares.

Summary

• James R. Gibson II, Chief Financial Officer of Pacific Biosciences of California, Inc. (PACB), received an equity grant on February 27, 2026.
• The grant includes 333,848 Restricted Stock Units (RSUs) and options to purchase 667,696 shares of common stock.
• The RSUs will vest in equal annual installments on February 15, 2027, 2028, and 2029, contingent on continued service.
• The stock options have an exercise price of $1.68 per share and will vest in 36 equal monthly installments starting March 27, 2026, also subject to continued service.
• Following these transactions, Mr. Gibson beneficially owns 1,333,848 shares of common stock and 667,696 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices that align management's interests with long-term shareholder value. It indicates stability in key leadership.

Positives

• The grant of 333,848 Restricted Stock Units (RSUs) and options for 667,696 shares aligns the Chief Financial Officer's interests with long-term shareholder value.
• The multi-year vesting schedules for both RSUs (through 2029) and stock options (36 monthly installments) incentivize continued service and performance from a key executive.
• The stock option exercise price of $1.68 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon James R. Gibson II's continued status as a service provider through the applicable vesting dates, meaning forfeiture if employment ceases.

Future Outlook

The multi-year vesting schedules for both the Restricted Stock Units and stock options indicate a long-term commitment from the Chief Financial Officer to the company's future performance and strategic objectives, extending through at least February 2029 for RSUs and March 2029 for options.

Management Comments

• James R. Gibson II, Chief Financial Officer, received an equity grant consisting of Restricted Stock Units and stock options.
• The vesting of these equity awards is subject to Mr. Gibson's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are a standard practice in the biotechnology and life sciences industry, particularly for growth-oriented companies like Pacific Biosciences. These grants are designed to align executive incentives with long-term shareholder value creation and to retain critical talent in a competitive market. The structure of RSUs and stock options with multi-year vesting schedules is typical for encouraging sustained performance.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech sector often include a mix of Restricted Stock Units (RSUs) and stock options, similar to this grant.
• Companies like Illumina (ILMN) and Danaher (DHR), while larger, also utilize performance-based equity awards with multi-year vesting to retain top talent and incentivize long-term growth.
• The vesting schedule, with annual RSU vesting over three years and monthly option vesting over three years, is a common structure seen across various technology and life science companies, aiming to balance retention with performance incentives.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU vesting and option exercise, but also increased alignment of CFO's interests with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to long-term strategy.

Next Steps

• Continued service by James R. Gibson II to meet vesting conditions for RSUs and stock options.
• Annual vesting of RSUs on February 15, 2027, 2028, and 2029.
• Monthly vesting of stock options beginning March 27, 2026, over 36 months.

Key Dates

Keywords

Pacific Biosciences, PACB, James R Gibson II, CFO, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Form 4, Executive Compensation